Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha ClinicAlpha Clinic ContactTrial SponsorDisease IndicationClinical Trial NameStatus of EnrollmentLearn More
UCSF
Carol Fraser-Brown
415-476-2188
carol.fraser-browne@ucsf.edu
Stanford University Severe Combined Innunodeficiency (SCID) AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients Recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Stratetech Burn wounds StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements No longer active
UCSF Talaris Transplanted Organ Rejection A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1) No longer active
City of Hope
Erminia Massarelli
626-218-9200
emassarelli@coh.org
Tessa Therapeutics Cancer - Nasopharyngeal Carcinoma A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngea Recruiting
UCSD Tigenix Crohn's Disease Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn’s Disease (CD) Active, not recruiting
City of Hope
Mihaela Cristea, MD
626-218-9200
mcristea@coh.org
Torque Therapeutics, Inc. Cancer - Lymphoma TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis B-Cell Leukemia A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies Active, not recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Cancer - Lymphoma (HIV-Related) Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Cancer - Tongue Dysphagia Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Eye - Retinopathy Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis/CIRM Spina bifida Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele Recruiting
UCLA
Scott Nowicki, MD, PhD

Ignacio Baselga Carretero, PhD
310-206-2090
IBaselga@mednet.ucla.edu
UCLA Cancer - Solid Tumors Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies No longer active
UCLA
Lia Etheridge
(310-825-7174)
letheridge@mednet.ucla.edu
UCLA Cancer - Lung A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC Active, not recruiting
UCLA
Sarah Larson, MD
310-206-8477
slarson@mednet.ucla.edu
UCLA Cancer TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) No longer active
UCLA
Caroline Kuo, MD
310-794-1940
ckuo@mednet.ucla.edu
UCLA X-linked Chronic Granulomatous Disease Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease Active, not recruiting
UCLA
Fabrizia Urbinati, PhD
(310) 794-1884
furbinati@ucla.edu
UCLA Sickle Cell Disease Stem Cell Gene Therapy for Sickle Cell Disease Recruiting
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
UCLA Severe Combined Immunodeficiency (SCID) Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) Active, not recruiting
UCSD
Barbara Parker, MD
858-822-6135
baparker@ucsd.edu

Rebecca Shatsky, MD
858-657-7000
rshatsky@ucsd.edu
UCSD Cancer - Breast Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer Active, not recruiting
UCSD & City of Hope UCSD Cancer - Leukemia A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Active, not recruiting
UCSD UCSD Cancer - Leukemia Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 No longer active
UCSD UCSD Cancer - Leukemia UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia No longer active
UCSD UCSD & CIRM Cystinosis Stem cell gene therapy for cystinosis Recruiting
UCSD
Benjamin M Heyman, MD
858-246-3038
bheyman@ucsd.edu
UCSD/Oncternal chronic lymphocytic leukemia Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax Active, not recruiting
UCSF
Kenny Truong
(415) 502-2080
Kenny.Truong@ucsf.edu
UCSF Graft versus Host Disease (GvHD) An Expanded Access Study of Using the CLINIMACS® Device for Alpha/Beta T-Cell Depletion in Stem Cell Transplant Recipients Recruiting
UCSF
Romobia Hutchinson
415-476-9326
romobia.hutchinson@ucsf.edu
UCSF Blood Disorder - Alpha Thalassemia Major In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) Recruiting
UC Davis & UCSD
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Viacyte Type 1 diabetes An Open-Label, First-in-Human, Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects with Type 1 Diabetes Mellitus and Hypoglycemia Unawareness No longer active
UCSD Viacyte Diabetes - Type 1 Three Year Follow-up Safety Study in Subjects Previously Implanted With VC-01 No longer active
UCSD Viacyte Diabetes - Type 1 A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness No longer active
UCSD Viacyte Diabetes - Type 1 A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus No longer active

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials. If you or a family member is interested in participating in a clinical trial, please visit clinicaltrials.gov to find a trial near you.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News